| scholarly article | Q13442814 |
| P50 | author | Pamela S. Hinds | Q88238145 |
| P2093 | author name string | Jichuan Wang | |
| Heather E Gross | |||
| Catherine Fiona Macpherson | |||
| Shana Jacobs | |||
| Yao Iris Cheng | |||
| Holly J Meany | |||
| Claire M Wharton | |||
| Emily Dunn Stern | |||
| Ruthanna Okorosobo | |||
| P2860 | cites work | Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance | Q29615569 |
| Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor | Q33380199 | ||
| Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia | Q33598078 | ||
| Methods for assessing responsiveness: a critical review and recommendations | Q33919427 | ||
| Decision making by parents of children with incurable cancer who opt for enrollment on a phase I trial compared with choosing a do not resuscitate/terminal care option | Q33990895 | ||
| Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes | Q34733490 | ||
| Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group | Q34915389 | ||
| Patterns of symptoms and functional impairments in children with cancer | Q35546731 | ||
| Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method | Q36414940 | ||
| Patient-reported outcomes in end-of-life research in pediatric oncology | Q36778421 | ||
| Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F). | Q36869748 | ||
| Patient-reported outcomes in cancer: a review of recent research and policy initiatives | Q36940399 | ||
| Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks | Q36996966 | ||
| Patient-reported outcomes supporting anticancer product approvals | Q36996981 | ||
| Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors | Q37104791 | ||
| A comparison of the theory of unpleasant symptoms and the conceptual model of chemotherapy-related changes in cognitive function | Q37366182 | ||
| Feasibility and acceptability of the patient-reported outcomes measurement information system measures in children and adolescents in active cancer treatment and survivorship. | Q37384877 | ||
| Responsiveness and minimally important difference for the patient-reported outcomes measurement information system (PROMIS) 20-item physical functioning short form in a prospective observational study of rheumatoid arthritis | Q37685913 | ||
| Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis | Q37806773 | ||
| Monitoring child and parent refusals to enrol in clinical research protocols | Q38409575 | ||
| Quality of life as conveyed by pediatric patients with cancer | Q38422129 | ||
| The PedsQL™* 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and Validity | Q39669138 | ||
| Clinical field testing of an enhanced-activity intervention in hospitalized children with cancer | Q40233942 | ||
| The middle-range theory of unpleasant symptoms: an update | Q41367844 | ||
| Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation | Q41971114 | ||
| PROMIS pediatric measures in pediatric oncology: valid and clinically feasible indicators of patient-reported outcomes | Q43486531 | ||
| Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. | Q47872951 | ||
| Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study | Q48285313 | ||
| Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia | Q48454641 | ||
| Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy | Q48459029 | ||
| Elementary school-aged children's reports of their health: a cognitive interviewing study. | Q51964379 | ||
| End-of-life care preferences of pediatric patients with cancer. | Q52039060 | ||
| Measuring change over time: assessing the usefulness of evaluative instruments. | Q52608136 | ||
| Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making. | Q53170281 | ||
| Bootstrap Methods: Another Look at the Jackknife | Q55950786 | ||
| The Need for Adverse Effects Reporting Standards in Oncology Clinical Trials | Q57618434 | ||
| Cancer-related symptoms most concerning to parents during the last week and last day of their child's life | Q81198545 | ||
| Characteristics and outcome of pediatric patients enrolled in phase I oncology trials | Q81543334 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 3799-3806 | |
| P577 | publication date | 2017-06-05 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint? | |
| P478 | volume | 123 |
Search more.